Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-07-03-Speech-2-501-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-07-03"^^xsd:date2
dcterms:Is Part Of	lp_eu:Anti-Counterfeiting Trade Agreement between the EU and its Member States, Australia, Canada, Japan, the Republic of Korea, Mexico, Morocco, New Zealand, Singapore, Switzerland and the USA (debate)2
dcterms:Language	"es"^^xsd:language2
lpv:document identification number	"en.20120703.21.2-501-000"2
lpv:hasSubsequent	lp_eu:2012-07-03-Speech-2-502-0002
lpv:speaker	lp:Ricardo Cortés Lastra2
lpv:spokenAs	member; Delegation to the Euro-Latin American Parliamentary Assembly (2010-12-09--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 chair; Delegation to the EU-Mexico Joint Parliamentary Committee (2010-11-11--2014-06-30)3 member; Conference of Delegation Chairs (2010-11-11--2014-06-30)3 unknown; Partido Socialista Obrero Español (2009-07-14--2014-06-30)3 substitute; AGRI (2012-01-19--2014-06-30)3 member; DEVE (2012-01-19--2014-06-30)3 substitute; Delegation for relations with Afghanistan (2009-09-16--2014-06-30)3
lpv:translated text	"Mr President, ‘no’ to the Anti-Counterfeiting Trade Agreement (ACTA). That was the majority decision of the Committee on Development at its last vote, and in reaching it we weighed up various issues, such as: firstly, that only 11 countries took part in the negotiations, therefore limiting its global impact, as the countries where the majority of counterfeits come from, as well as the majority of developing countries, are not parties to the agreement; secondly, that we need to go further than this agreement and prevent the negative impact that it could have on access to drugs and public health in developing countries, and also in the European Union. The more than likely negative impact of ACTA on public health has been written about and criticised on countless occasions by non-governmental organisations, by the United Nations Special Rapporteur on the Right to Health, and by Parliament. Access to attainable drugs remains a key priority for people on low and middle incomes worldwide. The ACTA Treaty requires the signatories to pass laws and regulations that pose a risk to the availability of and access to generic drugs. We have said ‘no’ because we need to ensure the coherence of the Union’s policies with its development policy and find other ways of protecting intellectual property rights."@en1
lpv:unclassifiedMetadata	"(The speaker agreed to take a blue-card question under Rule 149(8))"1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph